FIGURE 3.

A schematic illustration of the proposed treatment of SARS‐CoV‐2 through the use of multifunctional nanocarriers that deliver antiviral siRNA into the respiratory system to combat viral infection. The first step is the encapsulation of siRNA in nanocarriers, its formulation in aerosols and their packing like in, metered‐dose inhaler to facilitate their pulmonary delivery. Surface of multifunctional lipid based nanocarrier modified with targeting moiety to AT‐I, II or those have ACE2 receptor, customize their delivery into lungs cells. The second step is the attachment of the siRNA‐encapsulated lipid‐nanocarrier to desired cells/tissues. In the cytoplasm the exogenously delivered siRNA activates the RNA‐interference pathway which chop‐down targeted sites in viral genome leads to inhibit their infection